· National medical insurance products
· National Essential Drug Products

Specification: 5mg as C26H26F2N2
Drug category: Western medicine
National Health Insurance: Category A

Indications: 1. Insufficient cerebral blood supply, vertebral artery ischemia, after cerebral thrombosis, etc. 2, tinnitus, dizziness. 3. Migraine prevention. 4, epilepsy adjuvant therapy.

Pharmacology and toxicology:
This product is a calcium channel blocker. It can prevent cell damage caused by intracellular pathological calcium overload caused by ischemia and other reasons.
This product has:
Relief of vasospasm: It has a lasting inhibitory effect on persistent vasospasm caused by vasoconstrictor substances, especially on basilar artery and internal carotid artery, and its effect is 15 times stronger than that of cerebrolyzine;
Vestibular inhibition: can increase the blood flow of the cochlear arterioles and improve the circulation of the vestibular organs;
Anti-epileptic effect: This product can block the pathological calcium overload of nerve cells and prevent paroxysmal depolarization and cell discharge, thereby avoiding epileptic seizures;
Protect myocardium: significantly reduce ischemic myocardial damage;
The effect of improving renal function: it can be used for chronic renal failure;
In addition, this product also has antihistamine effect.